Xenon (XENE) has released an update.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, is set to announce its second quarter financial results for 2024 on August 8, following market close. Investors and interested parties can join the conference call and webcast scheduled for the same day. The company continues its commitment to developing treatments for neurological and psychiatric disorders, with its lead product, Azetukalner, in late-stage clinical development.
For further insights into XENE stock, check out TipRanks’ Stock Analysis page.
